{
    "clinical_study": {
        "@rank": "40051", 
        "acronym": "DAHANCA28A", 
        "arm_group": [
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Experimental", 
                "description": "Performance scale 0-1, Charlson co-morbidity score=0 Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole"
            }, 
            {
                "arm_group_label": "Group B", 
                "arm_group_type": "Experimental", 
                "description": "PS 0-1 Charlson=1 Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole"
            }, 
            {
                "arm_group_label": "Group C", 
                "arm_group_type": "Experimental", 
                "description": "PS 0-1 Charlson >=2 Will start inclusion after Group A and B Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole"
            }, 
            {
                "arm_group_label": "Group D", 
                "arm_group_type": "Experimental", 
                "description": "PS 2, Charlson: Any Will start inclusion after Group C Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole"
            }
        ], 
        "brief_summary": {
            "textblock": "P16 negative cancers continue to have a dismal prognosis despite advances in the treatment\n      of head and neck cancer. Acceleration, dose-escalation, hyperfractionation, chemotherapy and\n      nimorazole has been shown to improve local control. The purpose of the study i to\n      investigate the level of co-morbidity and performance status (PS) that allows the\n      combination of all of the above means of treatment intensification"
        }, 
        "brief_title": "Phase I/II Study on Accelerated, Hyperfractionated Radiotherapy With Concomitant Cisplatin and Nimorazole", 
        "completion_date": {
            "#text": "March 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "HNSCC,Larynx, Pharynx and Oral Cavity", 
        "condition_browse": {
            "mesh_term": "Neoplasms, Squamous Cell"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Squamous Cell Carcinoma head and neck cancer of the pharynx, larynx and oral cavity\n\n          -  P16 negative\n\n          -  T1-4\n\n          -  N1-3\n\n          -  M0\n\n          -  Organ function and performance status allowing radical chemo-radiotherapy\n\n        Exclusion Criteria:\n\n          -  None"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01733823", 
            "org_study_id": "DAHANCA 28A"
        }, 
        "intervention": {
            "arm_group_label": [
                "Group A", 
                "Group B", 
                "Group C", 
                "Group D"
            ], 
            "intervention_name": "76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole", 
            "intervention_type": "Radiation"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cisplatin", 
                "Nimorazole"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 1, 2013", 
        "location": [
            {
                "contact": {
                    "email": "kennjens@rm.dk", 
                    "last_name": "Kenneth Jensen, PhD", 
                    "phone": "+45 78460000"
                }, 
                "facility": {
                    "address": {
                        "city": "Aarhus", 
                        "country": "Denmark", 
                        "state": "Aarhus C", 
                        "zip": "8000"
                    }, 
                    "name": "Aarhus"
                }, 
                "investigator": {
                    "last_name": "Kenneth Jensen, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jesper Grau Eriksen, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Odense", 
                        "country": "Denmark", 
                        "state": "Odense C", 
                        "zip": "5000"
                    }, 
                    "name": "Odense"
                }, 
                "investigator": {
                    "last_name": "Jesper Grau Eriksen, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Lisbeth Juhler Andersen, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Aalborg", 
                        "country": "Denmark", 
                        "zip": "9100"
                    }, 
                    "name": "Aalborg"
                }, 
                "investigator": {
                    "last_name": "Lisbeth Juhler Andersen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Elo ANdersen, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Herlev", 
                        "country": "Denmark", 
                        "zip": "2730"
                    }, 
                    "name": "Herlev"
                }, 
                "investigator": {
                    "last_name": "Elo Andersen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "4", 
        "official_title": "Phase I/II Study on Accelerated, Hyperfractionated Radiotherapy With Concomitant Cisplatin and Nimorazole for Patients With Stage III-IV p16 Negative Squamous Cell Cancer (SCC) of the Larynx, Pharynx and Oral Cavity", 
        "overall_contact": {
            "email": "jens@oncology.dk", 
            "last_name": "Jens Overgaard, DrMSc", 
            "phone": "+45 78462620"
        }, 
        "overall_contact_backup": {
            "email": "kennjens@rm.dk", 
            "last_name": "Kenneth Jensen, PhD", 
            "phone": "+45 78460000"
        }, 
        "overall_official": {
            "affiliation": "Danish Head and Neck Cancer Group", 
            "last_name": "Jens Overgaard, DrMSc", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Denmark: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "March 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Proportion of patients that receive radiotherapy in accordance to prescribed dose and treatment time", 
            "measure": "Compliance", 
            "safety_issue": "Yes", 
            "time_frame": "End of radiotherapy (approximately 5.5 weeks after start of radiotherapy)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01733823"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "In accordance with the Danish Head and Neck Cancer Group (DAHANCA) toxicity scales", 
                "measure": "Acute toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "2 months after end of radiotherapy"
            }, 
            {
                "description": "Proportion of complete and partial responders", 
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "2 months after end of radiotherapy"
            }
        ], 
        "source": "Danish Head and Neck Cancer Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Danish Head and Neck Cancer Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}